Breast Cancer Patients on Endocrine Therapy Lose Less Weight on GLP-1 Drugs
A retrospective cohort of 269 breast cancer patients found that GLP-1 receptor agonists produced significant but markedly attenuated weight loss ...
A retrospective cohort of 269 breast cancer patients found that GLP-1 receptor agonists produced significant but markedly attenuated weight loss ...
A 2026 review finds that multi-agonist obesity drugs can produce substantial weight loss, but biomarker and pharmacogenomic tools are not ...
A large retrospective cohort found that hormone-therapy use was associated with greater, sustained semaglutide weight loss in midlife women, while ...
A new narrative review finds that GLP-1 receptor agonists like semaglutide and tirzepatide are safe and effective for weight loss ...
A new opinion article argues that inflammation may be the missing link explaining both the potential suicide risk and the ...
A new commentary in the Journal of Clinical Sleep Medicine argues that hours-per-night metrics fundamentally misrepresent how well patients actually ...
A meta-analysis of 37 phase 3 trials involving more than 50,000 adults finds that weight loss explains about 76 percent ...
New research presented at the 11th UK Congress on Obesity in Sheffield shows GLP-1 medications are reshaping treatment while behavioural ...
An indirect treatment comparison of the SURMOUNT-1 and STEP 1 trials finds tirzepatide 10 and 15 mg delivers greater weight ...
A JAMA cross-sectional study quantifies how frequently commercially insured women in the United States begin GLP-1 receptor agonist prescriptions after ...
Tirzepatide, a novel therapeutic agent, has emerged as a beacon of hope for individuals grappling with metabolic dysfunction-associated steatohepatitis (MASH). ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.